An official website of the United States government
A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma
Trial Status: active
This global, open-label, single arm, phase 1b study aims to learn more about whether a
treatment called JNJ-90301900 is safe and effective when injected directly into tumors,
along with standard chemotherapy and radiation therapy, for participants with head and
neck squamous cell cancer (HNSCC; a type of solid tumor that begins in outer tissue layer
of the mouth & throat).
Inclusion Criteria
Pathologically (histologically or cytologically) proven diagnosis of HNSCC of the oral cavity, oropharynx (p16 negative), hypopharynx, or supraglottic larynx
Stage III, IVA or IVB according to the 8th Edition of the American Joint Committee on Cancer (AJCC) guidelines
A candidate for definitive concurrent chemoradiation therapy treatment as determined by investigator and per local guidelines
Participants must have at least 1 target lesion (primary tumor or involved lymph node) per RECIST v.1.1
Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0 or 1
Exclusion Criteria
Primary tumor originating in the nasopharynx, paranasal sinuses, salivary glands, thyroid gland, parathyroid gland, skin, or unknown primary site
Non-squamous histology
Stages 0, I, II, and IVC HNSCC, loco-regionally recurrent HNSCC, or synchronous second primary HNSCC (within 2 months)
Ineligible to receive platinum-based chemotherapy
Suspected or known allergies, hypersensitivity, or intolerance to JNJ-90301900 or its excipients
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT07219212.
Locations matching your search criteria
United States
California
Duarte
City of Hope Comprehensive Cancer Center
Status: Active
Name Not Available
Florida
Jacksonville
Mayo Clinic in Florida
Status: Active
Name Not Available
Tampa
Moffitt Cancer Center
Status: Active
Name Not Available
Georgia
Atlanta
Emory University Hospital Midtown
Status: Active
Name Not Available
North Carolina
Chapel Hill
UNC Lineberger Comprehensive Cancer Center
Status: Active
Name Not Available
Pennsylvania
Philadelphia
University of Pennsylvania/Abramson Cancer Center
Status: Active
Name Not Available
Trial PhasePhase I
Trial Typetreatment
Lead OrganizationJohnson & Johnson Enterprise Innovation Inc.
